1529-0131a/asset/cover.gif?v=1&s=4b71f39689e424fbb0e6725b1c033cc646a4272b "Arthritis Care & Research")
Dr. Schumacher has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Takeda Global Research & Development Center, Inc., and Savient.
2151-4658/asset/olbannerleft.gif?v=1&s=75d1dd4933b4687fdb365bb32190b0a4ef453ee7)
2151-4658/asset/olbannerright.gif?v=1&s=a36ba6af41bd9af370864f6461a516746a709d31)
Gout
You have full text access to this OnlineOpen article
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial†‡
Article first published online: 30 OCT 2008
DOI: 10.1002/art.24209
Copyright © 2008 by the American College of Rheumatology
Additional Information
How to Cite
Schumacher, H. R., Becker, M. A., Wortmann, R. L., MacDonald, P. A., Hunt, B., Streit, J., Lademacher, C. and Joseph-Ridge, N. (2008), Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis & Rheumatism, 59: 1540–1548. doi: 10.1002/art.24209
- †
ClinicalTrials.gov identifier: NCT00174915.
- ‡
Previously published in abstract form: Schumacher HR, Becker MA, Wortmann RL, MacDonald PA, Hunt B, Streit J, et al. Febuxostat vs allopurinol and placebo in subjects with hyperuricemia and gout: the 28-week APEX study [abstract]. Arthritis Rheum 2005;52 Suppl 9:S680.
Publication History
- Issue published online: 30 OCT 2008
- Article first published online: 30 OCT 2008
- Manuscript Accepted: 10 JUN 2008
- Manuscript Received: 20 DEC 2007
Funded by
- Takeda Global Research & Development Center, Inc., Deerfield, Illinois
- Takeda Global Research & Development Center, Inc.
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , , , African American patients with gout: efficacy and safety of febuxostat vs allopurinol, BMC Musculoskeletal Disorders, 2012, 13, 1, 15
- 2, , , , , , Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal, Arthritis & Rheumatism, 2012, 64, 2Direct Link:
- 3, Les traitements hypo-uricémiants disponibles dans la goutte, Annales Pharmaceutiques Françaises, 2012,
- 4, , Pegloticase: a new biologic for treating advanced gout, International Journal of Clinical Rheumatology, 2012, 7, 2, 143
- 5, Treatment of Chronic Gouty Arthritis: It Is Not Just About Urate-Lowering Therapy, Seminars in Arthritis and Rheumatism, 2012,
- 6, , , , , Women with gout: Efficacy and safety of urate-lowering with febuxostat and allopurinol, Arthritis Care & Research, 2012, 64, 2Direct Link:
- 7
- 8
- 9
- 10, , , Allopurinol, uric acid, and oxidative stress in cardiorenal disease, International Urology and Nephrology, 2011, 43, 2, 441
- 11, An update on the pathology and clinical management of gouty arthritis, Clinical Rheumatology, 2011, 31, 1, 13
- 12
- 13
- 14, , Febuxostat for the treatment of hyperuricemia in patients with gout, International Journal of Clinical Rheumatology, 2011, 6, 5, 485
- 15, , , Febuxostat, ein neues Pharmakon zur Behandlung der Gicht, Der Kardiologe, 2011, 5, 1, 45
- 16, Gout measures: Gout Assessment Questionnaire (GAQ, GAQ2.0), and physical measurement of tophi, Arthritis Care & Research, 2011, 63, S11Direct Link:
- 17
- 18, , , Gout: Current Insights and Future Perspectives, The Journal of Pain, 2011, 12, 11, 1113
- 19, Goutte : mise en place et suivi du traitement hypo-uricémiant, Revue du Rhumatisme, 2011, 78, S142
- 20, , , , , , , Management of asymptomatic hyperuricaemia in patients with chronic kidney disease by Japanese nephrologists: A questionnaire survey, Nephrology, 2011, 16, 5Direct Link:
- 21, , Management of Gout in the Older Adult, The American Journal of Geriatric Pharmacotherapy, 2011, 9, 5, 271
- 22, , , Medical therapy for calculus disease, BJU International, 2011, 107, 3Direct Link:
- 23
- 24
- 25
- 26, Rising Gout, Life Threatening Public Enemy, Journal of Rheumatic Diseases, 2011, 18, 4, 234
- 27, , , Role of Melanocortin Receptors in the Regulation of Gouty Inflammation, Current Rheumatology Reports, 2011, 13, 2, 138
- 28, , , , , , Serum Urate as a Soluble Biomarker in Chronic Gout—Evidence that Serum Urate Fulfills the OMERACT Validation Criteria for Soluble Biomarkers, Seminars in Arthritis and Rheumatism, 2011, 40, 6, 483
- 29
- 30
- 31, , , , , , , Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment, Arthritis & Rheumatism, 2011, 63, 2Direct Link:
- 32
- 33
- 34, , Advances and unmet needs in gout, International Journal of Clinical Rheumatology, 2010, 5, 2, 187
- 35, Crystal Arthropathies: Recognizing and Treating “The Gouchâ€, Primary Care: Clinics in Office Practice, 2010, 37, 4, 703
- 36, Current and Future Therapeutic Options for the Management of Gout, American Journal of Therapeutics, 2010, 1
- 37
- 38, , , , , , , , , , , , , , International position paper on febuxostat, Clinical Rheumatology, 2010, 29, 8, 835
- 39, , , , , , , , , , , , , , International position paper on febuxostat, Clinical Rheumatology, 2010,
- 40, Progress in the pharmacotherapy of gout, Current Opinion in Rheumatology, 2010, 22, 2, 188
- 41, , , Rheumatologic sequelae and challenges in organ transplantation, Best Practice & Research Clinical Rheumatology, 2010, 24, 3, 329
- 42, , The Next Generation of Gout Therapeutics: Ready for Prime Time?, Current Rheumatology Reports, 2010, 13, 2, 100
- 43, , Update on gout and hyperuricemia, International Journal of Clinical Practice, 2010, 64, 3Direct Link:
- 44, Update on gout: new therapeutic strategies and options, Nature Reviews Rheumatology, 2010, 6, 1, 30
- 45, , , , Urate-Lowering Therapy for Gout: Focus on Febuxostat, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2010, 30, 6Direct Link:
- 46
- 47
- 48, Side Effects of Drugs Annual 32 - A worldwide yearly survey of new data and trends in adverse drug reactions and interactions, 2010,
- 49, , A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout, Current Rheumatology Reports, 2009, 11, 2, 135
- 50, , , , , , Cozzarelli Prize Winner@;DELIM@;From the Cover: Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout, Proceedings of the National Academy of Sciences, 2009, 106, 25, 10338
- 51
- 52
- 53, Febuxostat: a new treatment for hyperuricaemia in gout, Rheumatology, 2009, 48, Supplement 2, ii15
- 54, , Febuxostat: A selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout, Clinical Therapeutics, 2009, 31, 11, 2503
- 55
- 56, , Gout: new advances in the diagnosis and management of an old disease, International Journal of Clinical Rheumatology, 2009, 4, 2, 203
- 57, , , Kristallinduzierte Inflammasomaktivierung: Gicht und Pseudogicht, Zeitschrift für Rheumatologie, 2009, 68, 9, 733
- 58, , Update on emerging urate-lowering therapies, Current Opinion in Rheumatology, 2009, 21, 2, 143
- 59, Gout management: Let's get it right this time, Arthritis Care & Research, 2008, 59, 11Direct Link:
- 60, , Pegloticase for chronic gout, The Cochrane Library,Direct Link: